197 related articles for article (PubMed ID: 26374107)
1. Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.
Patel S; Steen D
J Thromb Thrombolysis; 2016 Feb; 41(2):285-92. PubMed ID: 26374107
[TBL] [Abstract][Full Text] [Related]
2. Who, when, and how to reverse non-vitamin K oral anticoagulants.
Aronis KN; Hylek EM
J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
[TBL] [Abstract][Full Text] [Related]
3. Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?
Washam JB; Piccini JP
J Thromb Thrombolysis; 2016 Feb; 41(2):279-84. PubMed ID: 26498170
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
Mo Y; Yam FK
Pharmacotherapy; 2015 Feb; 35(2):198-207. PubMed ID: 25644580
[TBL] [Abstract][Full Text] [Related]
5. The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran.
O'Malley PA
Clin Nurse Spec; 2016; 30(2):81-3; quiz E9. PubMed ID: 26848896
[No Abstract] [Full Text] [Related]
6. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
8. Reversal Agents in the Era of NOACs.
Abed HS; Kilborn MJ; Chen V; Sy RW
J Atr Fibrillation; 2017 Dec; 10(4):1634. PubMed ID: 29487678
[TBL] [Abstract][Full Text] [Related]
9. Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.
Eckman MH
J Thromb Thrombolysis; 2016 Feb; 41(2):234-40. PubMed ID: 26343041
[TBL] [Abstract][Full Text] [Related]
10. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
Weitz JI; Pollack CV
Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
[TBL] [Abstract][Full Text] [Related]
11. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes.
Becker RC
J Thromb Thrombolysis; 2016 Feb; 41(2):273-8. PubMed ID: 26476930
[No Abstract] [Full Text] [Related]
12. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
13. Reversal of antithrombotic agents.
Bauer KA
Am J Hematol; 2012 May; 87 Suppl 1():S119-26. PubMed ID: 22460529
[TBL] [Abstract][Full Text] [Related]
14. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
Ebright J; Mousa SA
Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
[TBL] [Abstract][Full Text] [Related]
15. New oral anticoagulants in practice: pharmacological and practical considerations.
Wang Y; Bajorek B
Am J Cardiovasc Drugs; 2014 Jun; 14(3):175-89. PubMed ID: 24452600
[TBL] [Abstract][Full Text] [Related]
16. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
18. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
Enriquez A; Lip GY; Baranchuk A
Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
[TBL] [Abstract][Full Text] [Related]
20. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
